InGel Therapeutics

InGel Therapeutics is creating novel stem cell based therapy to bring back light to patients suffering from diverse blinding diseases such as Dry-AMD and Retinitis Pigmentosa. Spin-out from Harvard Medical School, they have created novel pure stem cells and biomaterials to revolutionize the field of regenerative medicine in the eye. Their technologies have shown tremendous efficacy and safety in multiple animal studies and they are currently working towards their path to clinic and IND clearance from the FDA.

They are currently located at Lab Central where they have started our operations in September 2022 after winning the Boston Nucleate biotech cohort.